{"filings":[{"id":93114,"accession_number":"0001193125-26-211980","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Outset Medical Q1 revenue down 6% to $27.9M; gross margin expands to 43.4%","event_type":"earnings","confidence":"high","bullets":["Revenue $27.9M (-6% YoY); recurring revenue $22.5M roughly flat.","Gross margin 43.4% (up from 37.2% YoY); product gross margin record 52.4%, service margin record 25.5%.","Net loss narrowed to $19.0M from $25.8M; cash $161M at quarter end.","Reiterated FY 2026 revenue guidance $125-130M (5-9% growth) and non-GAAP gross margin low-to-mid 40%."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":27863000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104474,"accession_number":"0001193125-26-046588","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Outset Medical reports FY2025 revenue $119.5M (+5% YoY); provides 2026 guidance $125-130M","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $28.9M; full year 2025 revenue $119.5M (+5% YoY); recurring revenue $88.7M (+6%).","Gross margin expanded to 42.4% in Q4 (non-GAAP 42.9%), up ~600 bps vs Q4 2024.","Net loss narrowed to $81.7M in 2025 from $128M in 2024; cash $173M; ops cash burn $46M vs $116M.","Received FDA clearance for next-generation Tablo platform; launch expected in Q2 2026.","FY2026 guidance: revenue $125M-$130M (+5-9% YoY); non-GAAP gross margin low to mid-40%."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":119476000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104473,"accession_number":"0001193125-26-023428","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2026-01-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Outset Medical receives FDA 510(k) clearance for next-generation Tablo dialysis system; Q2 2026 launch","event_type":"regulatory","confidence":"high","bullets":["FDA 510(k) clearance granted for next-gen Tablo platform on January 27, 2026.","Tablo is first dialysis system to meet FDA's most rigorous cybersecurity guidance (June 2025).","Hardware, operating system, and software enhancements improve reliability and user experience.","Shipping to customers expected to begin in Q2 2026; current users eligible to upgrade.","CEO Leslie Trigg highlights milestone as reflecting commitment to innovation and patient safety."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104472,"accession_number":"0001193125-26-009865","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Outset Medical prelim Q4 rev $28.9M; FY2025 rev $119.5M (+5% YoY); cash $173M; appoints Prange","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue ~$28.9M; full-year 2025 revenue $119.5M, up 5% from $113.7M in 2024.","Year-end cash (incl. restricted cash & short-term investments) $173M; net cash used in ops <$50M vs $116M in 2024.","Over 1,000 sites insource dialysis with Outset; ~1M treatments/year; cumulative >3M treatments on Tablo.","Andrea Saia resigned from board effective Jan 9, 2026; Karen Prange appointed to board and Compensation Committee.","Prange brings med device exec experience (Henry Schein, Boston Scientific, Johnson & Johnson)."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":119476000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120763,"accession_number":"0001193125-25-274193","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Outset Medical Q3 revenue $29.4M (+3%); cuts FY 2025 revenue guidance to $115-120M","event_type":"earnings","confidence":"high","bullets":["Net loss $17.8M vs $27.9M a year ago; non-GAAP net loss $12M vs $20.2M.","Gross margin expanded to 39.4% (non-GAAP 39.9%) from 34.3% a year ago.","FY 2025 revenue guidance reduced to $115-120M from prior $122-126M.","Cash use improved to <$6M in Q3; total cash $182M at quarter end.","Operating expenses declined 19% YoY to $27.4M; path to profitability focus."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":90602000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137353,"accession_number":"0000950170-25-104054","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Outset Medical Q2 revenue up 15% to $31.4M; raises FY2025 guidance to $122-126M","event_type":"earnings","confidence":"high","bullets":["Net revenue $31.4M (+15% YoY); Tablo console revenue up 25%; recurring revenue $22.5M (+11%).","Non-GAAP gross margin 38.4% (+110bps); operating expenses down 29% YoY; net loss $18.5M vs $34.5M.","Raised 2025 revenue guidance to $122-126M from $115-125M; expects <$50M cash use vs >$100M in 2024.","New enterprise agreement with large national health system; Tablo now in >900 U.S. acute/sub-acute sites.","Cash $187.4M at June 30; H1 cash burn reduced ~60% vs prior year."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":61171000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154669,"accession_number":"0000950170-25-081009","cik":1484612,"company_name":"Outset Medical, Inc.","ticker":"OM","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["5.02","5.07","7.01","9.01"],"status":"ready","headline":"Outset Medical appoints Renee Gaeta as CFO; reaffirms $115M-$125M revenue guidance","event_type":"leadership","confidence":"high","bullets":["Renee Gaeta appointed CFO effective June 3, 2025; succeeds Nabeel Ahmed who is leaving.","Gaeta receives $500K base salary, $2.48M RSU award, and $620K PSU award.","2025 guidance reaffirmed: revenue $115M-$125M, non-GAAP gross margin in high-30% range.","Stockholders approved adding 1.95M shares to 2020 Equity Incentive Plan and 255K shares to ESPP."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}